Articles
-
2 weeks ago |
healio.com | Mark Leiser
Key takeaways: A supplemental podcast curriculum improved fellows’ comfort with four medical topics, including breast cancer and multiple myeloma. The intervention led to greater improvement in knowledge assessment scores. CHICAGO — A supplemental podcast curriculum improved hematology-oncology fellows’ comfort with and knowledge of medical topics, according to study results presented at ASCO Annual Meeting.
-
2 weeks ago |
healio.com | Mark Leiser
Key takeaways:Mid- to late-career medical oncologists from NCI-designated cancer centers delivered a high percentage of oral presentations. Findings demonstrate “considerable room” to improve diversity of podium presenters. CHICAGO — An analysis of oral presenters at ASCO Annual Meeting revealed considerable disparities based on career stage, gender, subspecialty and geographic region.
-
2 weeks ago |
healio.com | Mark Leiser
Key takeaways:An analysis of two matched cohorts found improved 1-year survival among those with higher BMI. Those with higher BMI also had reduced risk for ICU/hospital admission and several other complications. CHICAGO — A real-world analysis presented at ASCO Annual Meeting provided new insights into the effect BMI may have on how people with cancer respond to immunotherapy.
-
2 weeks ago |
healio.com | Mark Leiser
Key takeaways:41.7% of medical oncologists surveyed met criteria for burnout. Factors closely associated with burnout included negative impact of work on personal relationships, self-valuation and control over schedule. CHICAGO — More than four in 10 medical oncologists meet criteria for burnout, according to survey results presented at ASCO Annual Meeting. A comparable percentage met criteria for having professional fulfillment.
-
3 weeks ago |
healio.com | Mark Leiser
Key takeaways: Use of alternative endpoints in phase 3 oncology trials continues to increase. Just 28% of trials published in the past 20 years demonstrated OS improvement. CHICAGO — Positive interpretations of randomized phase 3 oncology trials often are based on improvements in unvalidated alternative endpoints, findings presented at ASCO Annual Meeting showed. Improvements in OS or quality of life are uncommon and they are “exceedingly rare in combination,” according to researcher Alexander D.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 12K
- Tweets
- 23K
- DMs Open
- No
Who’s being heard during #ASCO? 👩⚕️ 37.6% of presenters were women 📉13% of presenters were trainees or within 3 years of completing training 🩺Early-career #oncologists gave oral/rapid abstracts, but delivered 0⃣ plenary sessions #ASCO25 👇 https://t.co/raNIAHTix9
🎵🎶🎵 #MusicTherapy appeared as effective as cognitive behavioral therapy for reducing anxiety during #survivorship Jacek K. Pinski, MD, PhD, of @uscnorris @KECKSchool_USC shares perspective on the #ASCO25 findings. Read more 👇 https://t.co/ezCJ72xdR5 https://t.co/X5xJrBmkfI
In the latest episode of Oncology Overdrive: @SoniSmithMD talks with host @ShikhaJainMD at #ASCO about building the proper #mindset in your #earlycareer on when to say “yes” and “no” to new tasks. #podcast #healthcareresearch Listen now: https://t.co/WUDMzVQT7r https://t.co/SO70Xh7aNI